Reduction of ethylnitrosourea-induced neoplastic proliferation in rat trigeminal nerves by nerve growth factor.
Ethylnitrosourea administered to pregnant rats on the 21st day of gestation at a dose of 50 mg/kg resulted in early neoplastic proliferation or neurinomas of trigeminal nerves in 90% of the offspring at 90 days of age. Treatment with nerve growth factor either postnatally following ethylnitrosourea administration or transplacentally prior to ethylnitrosourea treatment appeared to result in a reduction of neurinomas at 90 days of age.
D000367:Age Factors; D000818:Animals; D003390:Cranial Nerve Neoplasms / Q000139:chemically induced* / Q000473:pathology; D005038:Ethylnitrosourea; D005260:Female; D005865:Gestational Age; D008431:Maternal-Fetal Exchange; D009374:Neoplasms, Experimental / Q000139:chemically induced; D009414:Nerve Growth Factors / Q000008:administration & dosage*; D009442:Neurilemmoma / Q000139:chemically induced* / Q000473:pathology; D009607:Nitrosourea Compounds; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000473:pathology; D011247:Pregnancy; D051381:Rats; D014276:Trigeminal Nerve
D009414:Nerve Growth Factors; D009607:Nitrosourea Compounds; D005038:Ethylnitrosourea